Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Clinical Trial Management
Regeneron Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California Irvine School of Medicine - Suite 400, Room 407
Orange, California, United States
- University of Colorado Hospital Anshutz Outpatient Pavillion
Denver, Colorado, United States
- Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building
Baltimore, Maryland, United States
- Sidney Kimmel Comprehensive Cancer Center - 4f Second Medical Building
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Henry Ford Hospital, Henry Ford Cancer Institute
Detroit, Michigan, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- Musc Hollings Cancer Center
Charleston, South Carolina, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Next Virginia
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Nov 2021
- Primary completion
- 15 Oct 2025
- Completion
- 15 Oct 2025
- Last update posted
- 3 Nov 2025
- Registered enrollment
- 30
- Registry id
- NCT04982224
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.